PP_1170x120_10-25-21

Yaz

Mylan adds to growing women’s healthcare portfolio

Mylan adds to growing women’s healthcare portfolio

HERTFORDSHIRE, England and PITTSBURGH — Global pharmaceutical company Mylan N.V. announced the U.S. launch of Drospirenone and Ethinyl Estradiol tablets USP, 3 mg/0.02 mg, a generic version of Bayer’s Yaz tablets. Mylan Pharmaceuticals received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which

Adheris Health